enGene Therapeutics (ENGN) Profit After Tax (2023 - 2026)

enGene Therapeutics (ENGN) has reported Profit After Tax for 4 consecutive years, with -$30.2 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Profit After Tax fell 17.09% year-over-year to -$30.2 million; the TTM figure through Apr 2026 stood at -$127.1 million (down 59.11% YoY), while the FY2025 annual figure was -$117.3 million, down 112.73% from the prior year.
• Profit After Tax eased to -$30.2 million in Q2 2026 per ENGN's latest filing, from -$29.8 million in the prior quarter.
• Across five years, Profit After Tax topped out at -$5.3 million in Q2 2023 and bottomed at -$82.5 million in Q4 2023.
• Historically, Profit After Tax has averaged -$23.8 million across 4 years, with a median of -$20.0 million in 2024.
• On a YoY basis, Profit After Tax climbed as much as 81.46% in 2024 and fell as far as 183.68% in 2024.
• enGene Therapeutics' Profit After Tax stood at -$82.5 million in 2023, then surged by 81.46% to -$15.3 million in 2024, then sank by 147.6% to -$37.9 million in 2025, then rose by 20.2% to -$30.2 million in 2026.
• Business Quant data shows ENGN's Profit After Tax at -$30.2 million in Q2 2026, -$29.8 million in Q1 2026, and -$37.9 million in Q4 2025.